CryoLife, Inc. (CRY) Q4 2020 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Lynn Lewis – Founder and Chief Executive Officer-Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief Financial Officer Conference Call Participants Suraj Kalia – Oppenheimer and Company Mike Matson – Needham and Company Jeffrey Cohen – Ladenburg Thalmann Operator Greetings, and welcome to the CryoLife’s Fourth Quarter Year End 2020 Financial Conference Call. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 CRYOLIFE INC. (Exact name of registrant as specified in its charter) Florida 59-2417093 (State o ...

CryoLife, Inc. (CRY) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Lynn Lewis – Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief Financial Officer Conference Call Participants Suraj Kalia – Oppenheimer Jeffrey Cohen – Ladenburg Thalmann Operator Greetings, and welcome to CryoLife’s Third Quarter 2020 Financial Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being re ...

Financial Data and Key Metrics Changes - Total revenues for Q2 2020 were $53.8 million, a decrease of 24% compared to Q2 2019, and a decrease of 23% on a constant currency basis [6][16] - Gross margins improved to 67% in Q2 2020 from 66% in Q2 2019, primarily due to a reduction in unit costs [16] - The company reported a net loss of approximately $3.7 million, or $0.10 per fully diluted share, with a non-GAAP net loss of $835,000, or $0.02 per share [17] Business Line Data and Key Metrics Changes - Tissue processing revenues decreased by 17%, On-X revenues decreased by 18%, BioGlue revenues decreased by 31%, and JOTEC revenues decreased by 23% compared to Q2 2019, all affected by the COVID-19 pandemic [16] - Monthly revenue performance showed improvement: April down 39%, May down 22%, and June down 15% compared to the same months in 2019 [7][10] Market Data and Key Metrics Changes - Revenue recovery was noted as hospitals resumed procedures starting in May, with optimism for continued improvement in Q3 and Q4 [6][10] - Asia performed best in Q2 compared to last year, while Latin America was the worst performer due to the pandemic's impact [38] Company Strategy and Development Direction - The company plans to continue investing in growth initiatives and R&D projects while managing expenses carefully [11][18] - Upcoming product launches include next-generation JOTEC products, with limited market releases already initiated [13] - The company is on track to file a PMA for PerClot in the U.S. and respond to the Chinese FDA for BioGlue by year-end [15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for Q3 and Q4, anticipating a strong year in 2021 based on current knowledge [8][19] - The company remains in a strong liquidity position, having completed a $100 million convertible debt offering [12][19] - Management emphasized the resilience of their product portfolio and the ability to adapt to the ongoing pandemic [60] Other Important Information - The company has implemented cost reduction initiatives, including hiring freezes and reductions in discretionary spending, while still investing in key clinical and R&D programs [18] - The company has maintained operations at or near capacity across its manufacturing sites, avoiding significant supply chain disruptions [11] Q&A Session Summary Question: Update on PROACT trial interest levels - Management noted high patient interest in the PROACT trial, which allows enrollment via telehealth, facilitating participation during the pandemic [23][25] Question: Commentary on NEXUS and U.S. trial timing - Management acknowledged that NEXUS faced setbacks due to travel restrictions for physician proctors but remains optimistic about its potential [29][30] Question: Update on On-X mitral trial - The On-X mitral trial completed enrollment at the end of last year, with data analysis expected in Q1 2021 [32] Question: JOTEC supply disruption status - Management confirmed that JOTEC supply issues have been resolved, with inventory levels up 32% [41] Question: July revenue performance and Northeast recovery - Management indicated that July performance is better than previous months, with strong recovery noted in the Northeast [46][48] Question: NeoPatch feedback and contribution expectations - Positive customer feedback has been received for NeoPatch, with expectations for a relaunch as conditions normalize [50]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 CRYOLIFE INC. (Exact name of registrant as specified in its charter) Florida 59-2417093 (State or oth ...

CryoLife, Inc. (CRY) Q1 2020 Earnings Conference Call April 30, 2020 4:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Pat Mackin - CEO Ashley Lee - CFO Conference Call Participants Jason Mills - Canaccord Genuity David Saxon - Needham and Company Suraj Kalia - Oppenheimer and Company Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the CryoLife 2020 first quarter financial conference call. [Operator instructions] As a reminder, this conference is being recorded. It is now m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 CRYOLIFE INC. (Exact name of registrant as specified in its charter) Florida 59-2417093 (State or ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation or or ...

CryoLife, Inc. (CRY) Q3 2019 Results Conference Call October 30, 2019 5:30 PM ET Company Participants Greg Chodaczek - Investor Relations Pat MacKin - Chief Executive Officer Ashley Lee - Chief Financial Officer Conference Call Participants Cecilia Furlong - Canaccord Genuity Mike Matson - Needham & Company Jeffrey Cohen - Landenburg Thalmann Brooks O'Neil - Lake Street Capital Joe Munda - First Analyst Suraj Kalia - Oppenheimer Operator Greetings. Welcome to CryoLife's Third Quarter 2019 Financial Conferen ...

| --- | --- | --- | --- | |-------|------------|----------------|-------| | | | | | | | | | | | | | | | | | | | | | | | 59-2417093 | | | | Employer | (I.R.S. | | | | No.) | Identification | | | | 30144 | | | | | (Zip Code) | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...